Niranjan Kanesa-thasan
Chief Tech/Sci/R&D Officer chez ICOSAVAX, INC.
Profil
Niranjan Kanesa-thasan is the founder of Kanesa LLC, which was founded in 2017.
He is currently the Chief Medical Officer at Icosavax, Inc. since 2018.
He was previously the Chief Medical Officer-North America & VP at Novartis Vaccines & Diagnostics, Inc. from 2007 to 2015, and the Vice President-Clinical Research & Development at GSK Vaccines from 2015 to 2017.
Dr. Kanesa-thasan has an undergraduate degree from The Johns Hopkins University, a graduate degree from Uniformed Services University of the Health Sciences, and a doctorate degree from The Johns Hopkins University School of Medicine.
Postes actifs de Niranjan Kanesa-thasan
| Sociétés | Poste | Début |
|---|---|---|
| ICOSAVAX, INC. | Chief Tech/Sci/R&D Officer | 01/09/2018 |
Anciens postes connus de Niranjan Kanesa-thasan
| Sociétés | Poste | Fin |
|---|---|---|
| Kanesa LLC | Founder | 01/08/2019 |
| GSK Vaccines | Chief Tech/Sci/R&D Officer | 01/08/2017 |
Novartis Vaccines & Diagnostics, Inc.
 Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01/01/2015 |
Formation de Niranjan Kanesa-thasan
| The Johns Hopkins University | Undergraduate Degree |
| Uniformed Services University of the Health Sciences | Graduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Novartis Vaccines & Diagnostics, Inc.
Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Health Technology |
Icosavax, Inc.
 Icosavax, Inc. Pharmaceuticals: MajorHealth Technology Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses on developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA. | Health Technology |
| GSK Vaccines | |
| Kanesa LLC |
